Seer, Inc.

    Jurisdiction
    United States
    ISIN
    US81578P1066 (SEER)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. Read full profile

    Fundamentals

    Net revenue
    €13.77M
    Gross margin
    49.5%
    EBIT
    -€75.98M
    EBIT margin
    -551.6%
    Net income
    -€70.32M
    Net margin
    -510.6%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €18.17M +31.9% -€49.51M -29.6%
    €27.31M +50.3% -€46.29M -6.5%
    €36.51M +33.7% -€42.60M -8.0%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Farokhzad Omid CEO AND CHAIR -34K $2.04 -$69.34K
    Horn David R. PRESIDENT & CFO -6.8K $2.04 -$13.93K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 826K $1.40M -18K Sell

    Earnings Calls

    Latest earnings call: August 7, 2025 (Q2 2025)

    Add to watchlist

    Notifications